|
2010 Journal Article Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 yearsGordon, Louisa G., Scuffham, Paul A., Beesley, Vanessa L., Green, Adele C., DeFazio, Anna, Wyld, David K., Clavarino, Alexandra M., Australian Ovarian Cancer Study Group and Webb, Penelope M. (2010). Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years. International Journal of Gynecological Cancer, 20 (5), 757-765. doi: 10.1111/IGC.0b013e3181dbd13f |
|
2010 Journal Article Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiformeFrancesconi, Alessandra B., Dupre, Simon, Matos, Marco, Martin, David, Hughes, Brett G., Wyld, David K. and Lickliter, Jason D. (2010). Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience, 17 (8), 970-974. doi: 10.1016/j.jocn.2009.12.009 |
|
2009 Journal Article Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancersHerbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel and Scott, Andrew M. (2009). Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clinical Cancer Research, 15 (21), 6709-6715. doi: 10.1158/1078-0432.CCR-09-0536 |
|
2009 Journal Article Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 TrialAu, Heather-Jane, Karapetis, Christos S., O'Callaghan, Chris J., Tu, Dongsheng, Moore, Malcolm J., Zalcberg, John R., Kennecke, Hagen, Shapiro, Jeremy D., Koski, Sheryl, Pavlakis, Nick, Charpentier, Danielle, Wyld, David, Jefford, Michael, Knight, Gregory J., Magoski, Nadine M., Brundage, Michael D. and Jonker, Derek J. (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27 (11), 1822-1828. doi: 10.1200/JCO.2008.19.6048 |
|
2009 Journal Article Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosisFrancesconi, Alessandra Bastian, Matos, Marco, Lee, Joseph C., Wyld, David K., Clouston, Andrew D. and Macfarlane, David (2009). Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Annals of Nuclear Medicine, 23 (5), 497-499. doi: 10.1007/s12149-009-0252-6 |
|
2008 Conference Publication Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancerLickliter, J., Francesconi, A., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Wilks, A., Wyld, D. and Vasey, P. (2008). Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer. 2008 ASCO Annual Meeting, Chicago, IL, U.S.A., 30 May - 3 June, 2008. Alexandria, VA. U.S.A.: American Society of Clinical Oncology. |
|
2007 Journal Article Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trialStockler, M. R., O'Connell, R., Nowak, A. K., Goldstein, D., Turner, J., Wilcken, N. R. C., Wyld, D., Abdi, E., Glasgow, A., Beale, P. J., Jefford, M., Dhillon, H., Heritier, S., Carter, C., Hickie, I. B. and Simes, R. J. (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8 (7), 603-612. doi: 10.1016/S1470-2045(07)70148-1 |
|
2007 Journal Article A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanomaKefford, Richard, Beith, Jane McNeil, Van Hazel, Guy Arthur, Millward, Michael, Trotter, James Marshall, Wyld, David Keith, Kusic, Rada, Shreeniwas, Revati, Morganti, Adele, Ballmer, Andrea, Segal, Eleonor, Nayler, Oliver and Clozel, Martine (2007). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Investigational New Drugs, 25 (3), 247-252. doi: 10.1007/s10637-006-9014-7 |
|
2007 Journal Article Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancerFriedlander, M, Buck, M, Wyld, D, Findlay, M, Fitzharris, B, De Souza, P, Davies, T, Kalimi, G, Allan, S, Perez, D and Harnett, P (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer, 17 (2), 350-358. doi: 10.1111/j.1525-1438.2007.00795.x |
|
2006 Journal Article Metastatic paraganglioma with extensive bone marrow involvementMorris, Kirk L., Macfarlane, David, Wyld, David and Kennedy, Glen A. (2006). Metastatic paraganglioma with extensive bone marrow involvement. Asia-Pacific Journal of Clinical Oncology, 2 (4), 193-194. doi: 10.1111/j.1743-7563.2006.00068.x |
|
2005 Conference Publication Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.Sabesan, SS, Wyld, D, Herath, N and Boyd, A (2005). Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.. 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando Fl, May 13-17, 2005. AMER SOC CLINICAL ONCOLOGY. |
|
2005 Conference Publication A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanomaKefford, R, Beith, J, Van Hazel, GA, Millward, M, Trotter, J, Wyld, D, Kusic, R, Coward, J, Shreeniwas, R and Morganti, A (2005). A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanoma. ESMO Scientific and Educational Conference (ESEC), Budapest Hungary, Jun 02-05, 2005. OXFORD: OXFORD UNIV PRESS. |
|
2004 Journal Article Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancerLe Chevalier, T., Arriagada, R., Le Pechoux, C., Grunenwald, D., Dunant, A., Pignon, J. P., Tarayre, M., Abratt, R., Arriagada, R., Bergman, B., Gralla, R., Grunenwald, D., Le Chevalier, T., Orlowski, T., Papadakis, E., Pinel, M. I. Sathler, Araujo, C., Della Torre, H., de Solchaga, M. Masetto, Abdi, E., Blum, R., Ball, D., Basser, R., De Boer, R., Bishop, J., Brigham, B., Davis, S., Fox, D., Richardson, G. ... Wedel, H. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 350 (4), 351-360. doi: 10.1056/NEJMoa031644 |
|
2000 Journal Article Conquering chemotherapyHorwood, Keith and Wyld, David (2000). Conquering chemotherapy. Australian Prescriber, 23 (3). |
|
2000 Journal Article Conquering chemotherapy [3] (multiple letters)Allison, R., Horwood, K. and Wyld, D. (2000). Conquering chemotherapy [3] (multiple letters). Australian Prescriber, 23 (3). |
|
2000 Journal Article Cisplatin-based therapy: A neurological and neuropsychological reviewTroy, L., McFarland, K., Littman-Power, S., Kelly, B.J., Walpole, E.T., Wyld, D. and Thomson, D. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-oncology, 9 (1), 29-39. doi: 10.1002/(SICI)1099-1611(200001/02)9:1 |
|
2000 Journal Article Cisplatin-based therapy: A neurological and neurophysical reviewTroy, L., McFarland, K. A., Littman-Powers, S., Kelly, B. J., Walpole, E. T., Wyld, D. and Thomson, D. (2000). Cisplatin-based therapy: A neurological and neurophysical review. Psychooncology, 9 (1), 29-39. doi: 10.1002/(SICI)1099-1611(200001/02)9:1 |
|
1999 Book Chapter The impact of Cisplatin-based chemotherapy on everyday attentionTroy, L., Littmann-Power, S. C., Kelly, B. J., Thomson, D. and Wyld, D. (1999). The impact of Cisplatin-based chemotherapy on everyday attention. Brain Impairment and Rehabilitation: A National Perspective. (pp. 140-142) Brisbane: Aust. Academic Press. |
|
1998 Journal Article Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20Wyld, DK, Selby, P, Perren, TJ, Jonas, SK, Allen-Mersh, TG, Wheeldon, J and Burchill, SA (1998). Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. International Journal of Cancer, 79 (3), 288-293. doi: 10.1002/(SICI)1097-0215(19980619)79:33.3.CO;2-2 |
|
1998 Book Chapter Breast cancerWyld, D. (1998). Breast cancer. Key Topics in Oncology. (pp. 30-36) edited by G D Hall, P M Patel and A S Protheroe. Oxford, United Kingdom: Bios Scientific Publication. |
